We are live on ! Find out more

1,993 hedge funds and large institutions have $152B invested in Pfizer in 2016 Q2 according to their latest regulatory filings, with 125 funds opening new positions, 821 increasing their positions, 837 reducing their positions, and 83 closing their positions.

New
Increased
Maintained
Reduced
Closed

51% more first-time investments, than exits

New positions opened: 125 | Existing positions closed: 83

43% more funds holding in top 10

Funds holding in top 10: 200286 (+86)

11% more capital invested

Capital invested by funds: $136B → $152B (+$15.6B)

1% more funds holding

Funds holding: 1,9691,993 (+24)

0% less call options, than puts

Call options by funds: $2.54B | Put options by funds: $2.54B

2% less repeat investments, than reductions

Existing positions increased: 821 | Existing positions reduced: 837

3.02% less ownership

Funds ownership: 74.02%71% (-3%)

Holders
1,993
Holders Change
+24
Holders Change %
+1.22%
% of All Funds
53.06%
Holding in Top 10
286
Holding in Top 10 Change
+86
Holding in Top 10 Change %
+43%
% of All Funds
7.61%
New
125
Increased
821
Reduced
837
Closed
83
Calls
$2.54B
Puts
$2.54B
Net Calls
-$1.2M
Net Calls Change
+$286M

PFE Hedge Fund Activity: Q2 2016 in Review

1,993 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q2 2016, worth a combined $152B — up 11% from $136B a quarter earlier.

Buyers outnumbered sellers: 125 funds opened new PFE positions and 83 closed out — a net gain of 42 holders — while 821 added to existing stakes and 837 trimmed.

The largest buyer was Maverick Capital, adding an estimated $343M. The largest seller was Goldman Sachs, cutting an estimated $2.27B.

  • 1,993 institutional investors held Pfizer (PFE) as of Q2 2016, up from 1,969 in Q1 2016.
  • Funds reported $152B of Pfizer stock for Q2 2016, up 11% quarter-over-quarter.
  • 125 funds opened new Pfizer positions in Q2 2016 and 83 closed out, a net change of +42 holders.
  • The largest Pfizer buyer in Q2 2016 was Maverick Capital, an estimated $343M added.
  • The largest Pfizer seller in Q2 2016 was Goldman Sachs, an estimated $2.27B sold.

Based on aggregated 13F filings for Q2 2016.